BRIEF-Merck Announces Phase 3 Keynote-B96 Trial Met Primary Endpoint Of Progression-Free Survival (Pfs) In Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed Pd-L1 And In All Comers

Reuters
15 May
BRIEF-Merck Announces Phase 3 Keynote-B96 Trial Met Primary Endpoint Of Progression-Free Survival (Pfs) In Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed Pd-L1 And In All Comers

May 15 (Reuters) - Merck & Co Inc MRK.N:

  • MERCK ANNOUNCES PHASE 3 KEYNOTE-B96 TRIAL MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL $(PFS)$ IN PATIENTS WITH PLATINUM-RESISTANT RECURRENT OVARIAN CANCER WHOSE TUMORS EXPRESSED PD-L1 AND IN ALL COMERS

  • MERCK & CO INC - STUDY MEETS SECONDARY ENDPOINT OF OVERALL SURVIVAL

Source text: ID:nBw5Y4q6Va

Further company coverage: MRK.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10